CORE Biomedicine, Inc. Selected to Present at the 2025 ALIGN Summit Hosted by MassBio
Boston, MA – Sep 15, 2025 — CORE Biomedicine, Inc. is proud to announce its selection as a presenting company at the prestigious 2025 ALIGN Summit, an annual life sciences innovation and partnering conference hosted by the Massachusetts Biotechnology Council (MassBio). The event will take place on October 7, 2025, at the Boston Marriott Copley Place in Boston, MA.
The ALIGN Summit is recognized as a premier gathering that brings together emerging life sciences companies, funders, investors, and strategic partners to showcase cutting-edge science, foster high-impact collaborations, and advance breakthrough therapeutics and technologies. More than 50 seed through Series B companies are selected to present across thematic tracks focused on transformative innovation within the biotech ecosystem.
“As an organization focused on advancing novel biomedical solutions, CORE Biomedicine, Inc. is honored to be selected to present at the 2025 ALIGN Summit,” said Dr. Douglas McMillin, Co-founder and Head of Business Development at CORE Biomedicine, Inc. “This opportunity will allow us to share our latest scientific progress, connect with thought leaders and investors, and position our work within the broader narrative of innovation shaping the future of healthcare.”
CORE Biomedicine, Inc. will present its technology and pipeline during the dedicated company pitch sessions, highlighting its strategic vision, scientific achievements, and future milestones.
For more details on the ALIGN Summit, including the full program and agenda, please visit the official event page: https://www.massbio.org/innovation-align-summit/.
About CORE Biomedicine, Inc.
Founded by the former leadership of H3 Biomedicine, CORE Biomedicine, Inc. is building the next wave of oncology innovation by going beyond precision medicine. CORE’s lineage-based therapeutic platform targets the fundamental biological programs that define cancer cell identity, enabling the discovery of first- and best-in-class medicines with the potential to reach significantly larger patient populations.
Contact: contact@corebiomedicine.com